Over the past decade, psychedelic therapy has seen a resurgence of interest from the scientific and medical communities, with accumulating evidence supporting its safety and efficacy in treating various conditions, including substance use disorder (SUD). Research dating back to the mid-20th century has highlighted the therapeutic potential of both classic psychedelics, such as LSD, psilocybin, DMT, ayahuasca, and mescaline, as well as newer non-classic psychedelics like ketamine, MDMA and ibogaine.

Join the Substance Use Interest Group on Thursday, June 13, from 1 to 2 p.m. ET as we welcome Dr. Sandeep Nayak, Medical Director of the Johns Hopkins Center for Psychedelic & Consciousness Research, to explore the emerging science of using psychedelics in addiction treatment. Our discussion will cover the historical context and evolution of the field, foundational information on psychedelic therapy for SUD, past and emerging research, the diverse cultural contexts in which psychedelics are used, and the current regulatory landscape for using psychedelics in addiction treatment. We will also delve into specific research findings on the use of psilocybin for reducing illicit opioid use, improving quality of life, smoking cessation and addressing comorbidity in depression and alcohol use.


Dr. Sandeep Nayak

Medical Director of the Johns Hopkins Center for

Psychedelic & Consciousness Research



Alexandra Plante

Substance Use Interest Group Staff Lead

Senior Advisor, Substance Use Disorders, National Council for Mental Wellbeing

Mark Fontaine

Substance Use Interest Group Board Liaison

Consultant, Florida Behavioral Health Association